{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:39:45Z","timestamp":1783463985594,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>When hepatocellular carcinoma (HCC) cells exhibit malignant biological behaviors, lipid metabolic reprogramming occurs concomitantly. Thus, identifying regulators of metabolic reprogramming offers new potential targets for therapy. In this study, we investigated the mechanisms by which Cyclic adenosine monophosphate-responsive element binding protein 3-like 2(CREB3L2) influences HCC progression and contributes to lenvatinib resistance through modulation of lipid metabolism. Up-regulated expression of CREB3L2 was observed in numerous HCC cohorts and associated with poor survival prognosis of patients. Furthermore, CREB3L2 could facilitate the proliferation and metastatic capacity of HCC cells both in vitro and in vivo. It was found that CREB3L2 influences the proliferation and metastasis of HCC cells by up-regulating sterol regulatory element binding protein 1 (SREBP1), a vital regulatory factor of lipid synthesis for fatty acid production. Additionally, CREB3L2 enhances SREBP1 protein expression and stability through increased acetylation mediated by histone acetyltransferase-1(HAT1). Importantly, targeting CREB3L2 in combination with lenvatinib significantly reduced lenvatinib resistance, inhibiting the progression of CREB3L2 high-expressing HCC tumors. These findings suggest that the CREB3L2\/HAT1\/SREBP1 regulatory axis drives lenvatinib resistance and HCC progression by impacting lipid metabolism. Targeting CREB3L2 alongside lenvatinib improves the efficacy of treating HCC.<\/jats:p>","DOI":"10.1038\/s41419-025-08250-3","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T17:18:55Z","timestamp":1764004735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeting CREB3L2-mediated lipid metabolism overcomes lenvatinib resistance and attenuates the progression of hepatocellular carcinoma"],"prefix":"10.1038","volume":"16","author":[{"given":"Shiguang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengwei","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9953-988X","authenticated-orcid":false,"given":"Qifeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiafeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1283-3547","authenticated-orcid":false,"given":"Yichao","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3393-1322","authenticated-orcid":false,"given":"Weiren","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7342-4877","authenticated-orcid":false,"given":"Yuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1833-8988","authenticated-orcid":false,"given":"Yinghong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"8250_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31288","volume":"73","author":"KA McGlynn","year":"2021","unstructured":"McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73:4\u201313.","journal-title":"Hepatology"},{"key":"8250_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ebiom.2019.07.058","volume":"46","author":"D Wang","year":"2019","unstructured":"Wang D, Zheng X, Fu B, Nian Z, Qian Y, Sun R, et al. Hepatectomy promotes recurrence of liver cancer by enhancing IL-11-STAT3 signaling. EBioMedicine. 2019;46:119\u201332.","journal-title":"EBioMedicine"},{"key":"8250_CR3","doi-asserted-by":"publisher","first-page":"5464","DOI":"10.7150\/thno.54822","volume":"11","author":"FH Kong","year":"2021","unstructured":"Kong FH, Ye QF, Miao XY, Liu X, Huang SQ, Xiong L, et al. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. Theranostics. 2021;11:5464\u201390.","journal-title":"Theranostics"},{"key":"8250_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.mito.2023.01.001","volume":"69","author":"BS Smith","year":"2023","unstructured":"Smith BS, Hewitt T, Bakovic M, Lu R. ER stress-associated transcription factor CREB3 is essential for normal Ca(2+), ATP, and ROS homeostasis. Mitochondrion. 2023;69:10\u201317.","journal-title":"Mitochondrion"},{"key":"8250_CR5","doi-asserted-by":"crossref","unstructured":"Martin LJ, Nguyen HT. Basic leucine zipper transcription factors are important regulators of Leydig cells\u2019 functions. Int J Mol Sci.2022;23:12887\u2013913.","DOI":"10.3390\/ijms232112887"},{"key":"8250_CR6","doi-asserted-by":"publisher","first-page":"7156","DOI":"10.1158\/0008-5472.CAN-08-1085","volume":"68","author":"WO Lui","year":"2008","unstructured":"Lui WO, Zeng L, Rehrmann V, Deshpande S, Tretiakova M, Kaplan EL, et al. CREB3L2-PPARgamma fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis. Cancer Res. 2008;68:7156\u201364.","journal-title":"Cancer Res"},{"key":"8250_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.molcel.2013.11.008","volume":"53","author":"A Saito","year":"2014","unstructured":"Saito A, Kanemoto S, Zhang Y, Asada R, Hino K, Imaizumi K. Chondrocyte proliferation regulated by secreted luminal domain of ER stress transducer BBF2H7\/CREB3L2. Mol Cell. 2014;53:127\u201339.","journal-title":"Mol Cell"},{"key":"8250_CR8","doi-asserted-by":"publisher","first-page":"6479","DOI":"10.1038\/s41388-021-02026-7","volume":"40","author":"L Hu","year":"2021","unstructured":"Hu L, Chen X, Narwade N, Lim MGL, Chen Z, Tennakoon C, et al. Single-cell analysis reveals androgen receptor regulates the ER-to-Golgi trafficking pathway with CREB3L2 to drive prostate cancer progression. Oncogene. 2021;40:6479\u201393.","journal-title":"Oncogene"},{"key":"8250_CR9","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1158\/1078-0432.CCR-11-0145","volume":"17","author":"E M\u00f6ller","year":"2011","unstructured":"M\u00f6ller E, Hornick JL, Magnusson L, Veerla S, Domanski HA, Mertens F. FUS-CREB3L2\/L1-positive sarcomas show a specific gene expression profile with upregulation of CD24 and FOXL1. Clin Cancer Res. 2011;17:2646\u201356.","journal-title":"Clin Cancer Res"},{"key":"8250_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346.","journal-title":"Cancer Discov"},{"key":"8250_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2013.05.017","volume":"18","author":"E Currie","year":"2013","unstructured":"Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr. Cellular fatty acid metabolism and cancer. Cell Metab. 2013;18:153\u201361.","journal-title":"Cell Metab"},{"key":"8250_CR12","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrc2222","volume":"7","author":"JA Menendez","year":"2007","unstructured":"Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7:763\u201377.","journal-title":"Nat Rev Cancer"},{"key":"8250_CR13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nature10642","volume":"481","author":"AR Mullen","year":"2011","unstructured":"Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature. 2011;481:385\u20138.","journal-title":"Nature"},{"key":"8250_CR14","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nature10602","volume":"481","author":"CM Metallo","year":"2011","unstructured":"Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 2011;481:380\u20134.","journal-title":"Nature"},{"key":"8250_CR15","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1053\/j.gastro.2013.01.054","volume":"144","author":"A Budhu","year":"2013","unstructured":"Budhu A, Roessler S, Zhao X, Yu Z, Forgues M, Ji J, et al. Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology. 2013;144:1066\u20131075.e1061.","journal-title":"Gastroenterology"},{"key":"8250_CR16","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.ejca.2004.12.037","volume":"41","author":"N Yahagi","year":"2005","unstructured":"Yahagi N, Shimano H, Hasegawa K, Ohashi K, Matsuzaka T, Najima Y, et al. Coordinate activation of lipogenic enzymes in hepatocellular carcinoma. Eur J Cancer. 2005;41:1316\u201322.","journal-title":"Eur J Cancer"},{"key":"8250_CR17","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1002\/hep.30030","volume":"68","author":"C Wang","year":"2018","unstructured":"Wang C, Tong Y, Wen Y, Cai J, Guo H, Huang L, et al. Hepatocellular carcinoma-associated protein TD26 interacts and enhances sterol regulatory element-binding protein 1 activity to promote tumor cell proliferation and growth. Hepatology. 2018;68:1833\u201350.","journal-title":"Hepatology"},{"key":"8250_CR18","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1016\/j.ymthe.2022.02.021","volume":"30","author":"Y Yang","year":"2022","unstructured":"Yang Y, Cai J, Yang X, Wang K, Sun K, Yang Z, et al. Dysregulated m6A modification promotes lipogenesis and development of non-alcoholic fatty liver disease and hepatocellular carcinoma. Mol Ther. 2022;30:2342\u201353.","journal-title":"Mol Ther"},{"key":"8250_CR19","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"8250_CR20","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1158\/0008-5472.CAN-21-4140","volume":"82","author":"B Hu","year":"2022","unstructured":"Hu B, Zou T, Qin W, Shen X, Su Y, Li J, et al. Inhibition of EGFR overcomes acquired lenvatinib resistance driven by STAT3-ABCB1 signaling in hepatocellular carcinoma. Cancer Res. 2022;82:3845\u201357.","journal-title":"Cancer Res"},{"key":"8250_CR21","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","volume":"595","author":"H Jin","year":"2021","unstructured":"Jin H, Shi Y, Lv Y, Yuan S, Ramirez CFA, Lieftink C, et al. EGFR activation limits the response of liver cancer to lenvatinib. Nature. 2021;595:730\u20134.","journal-title":"Nature"},{"key":"8250_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1136\/gutjnl-2017-315348","volume":"68","author":"JH Lee","year":"2019","unstructured":"Lee JH, Suh JH, Choi SY, Kang HJ, Lee HH, Ye BJ, et al. Tonicity-responsive enhancer-binding protein promotes hepatocellular carcinogenesis, recurrence and metastasis. Gut. 2019;68:347\u201358.","journal-title":"Gut"},{"key":"8250_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01315-9","volume":"20","author":"XD Yang","year":"2021","unstructured":"Yang XD, Kong FE, Qi L, Lin JX, Yan Q, Loong JHC, et al. PARP inhibitor olaparib overcomes sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma. Mol Cancer. 2021;20:20.","journal-title":"Mol Cancer"},{"key":"8250_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16781-w","volume":"11","author":"K Huang","year":"2020","unstructured":"Huang K, Miao T, Chang K, Kim J, Kang P, Jiang Q, et al. Impaired peroxisomal import in Drosophila oenocytes causes cardiac dysfunction by inducing upd3 as a peroxikine. Nat Commun. 2020;11:2943.","journal-title":"Nat Commun"},{"key":"8250_CR25","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nrc.2016.89","volume":"16","author":"F R\u00f6hrig","year":"2016","unstructured":"R\u00f6hrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer. 2016;16:732\u201349.","journal-title":"Nat Rev Cancer"},{"key":"8250_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/hep.29778","volume":"68","author":"H Zheng","year":"2018","unstructured":"Zheng H, Pomyen Y, Hernandez MO, Li C, Livak F, Tang W, et al. Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma. Hepatology. 2018;68:127\u201340.","journal-title":"Hepatology"},{"key":"8250_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17818-w","volume":"11","author":"Q Xu","year":"2020","unstructured":"Xu Q, Li Y, Gao X, Kang K, Williams JG, Tong L, et al. HNF4\u03b1 regulates sulfur amino acid metabolism and confers sensitivity to methionine restriction in liver cancer. Nat Commun. 2020;11:3978.","journal-title":"Nat Commun"},{"key":"8250_CR28","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1172\/JCI0215593","volume":"109","author":"JD Horton","year":"2002","unstructured":"Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109:1125\u201331.","journal-title":"J Clin Invest"},{"key":"8250_CR29","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cmet.2012.09.002","volume":"16","author":"W Shao","year":"2012","unstructured":"Shao W, Espenshade PJ. Expanding roles for SREBP in metabolism. Cell Metab. 2012;16:414\u20139.","journal-title":"Cell Metab"},{"key":"8250_CR30","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1158\/0008-5472.CAN-21-2934","volume":"82","author":"EHK Mok","year":"2022","unstructured":"Mok EHK, Leung CON, Zhou L, Lei MML, Leung HW, Tong M, et al. Caspase-3-induced activation of SREBP2 drives drug resistance via promotion of cholesterol biosynthesis in hepatocellular carcinoma. Cancer Res. 2022;82:3102\u201315.","journal-title":"Cancer Res"},{"key":"8250_CR31","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1038\/s41418-023-01226-w","volume":"30","author":"Y Pi","year":"2023","unstructured":"Pi Y, Feng Q, Sun F, Wang Z, Zhao Y, Chen D, et al. Loss of SMURF2 expression enhances RACK1 stability and promotes ovarian cancer progression. Cell Death Differ. 2023;30:2382\u201392.","journal-title":"Cell Death Differ"},{"key":"8250_CR32","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1080\/15548627.2022.2148432","volume":"19","author":"F Yi","year":"2023","unstructured":"Yi F, Cai C, Ruan B, Hao M, Yeo SK, Haas M, et al. Regulation of RB1CC1\/FIP200 stability and autophagy function by CREBBP-mediated acetylation in an intrinsically disordered region. Autophagy. 2023;19:1662\u201377.","journal-title":"Autophagy"},{"key":"8250_CR33","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.apsb.2021.09.019","volume":"12","author":"D Du","year":"2022","unstructured":"Du D, Liu C, Qin M, Zhang X, Xi T, Yuan S, et al. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharm Sin B. 2022;12:558\u201380.","journal-title":"Acta Pharm Sin B"},{"key":"8250_CR34","doi-asserted-by":"crossref","unstructured":"Foglia B, Beltr\u00e0 M, Sutti S, Cannito S. Metabolic reprogramming of hcc: a new microenvironment for immune responses. Int J Mol Sci. 2023;24:7463\u201387.","DOI":"10.3390\/ijms24087463"},{"key":"8250_CR35","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","volume":"18","author":"RL Setten","year":"2019","unstructured":"Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18:421\u201346.","journal-title":"Nat Rev Drug Discov"},{"key":"8250_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-022-01309-9","volume":"20","author":"K Mahmoud","year":"2022","unstructured":"Mahmoud K, Swidan S, El-Nabarawi M, Teaima M. Lipid-based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances. J Nanobiotechnology. 2022;20:109.","journal-title":"J Nanobiotechnology"},{"key":"8250_CR37","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nchembio.1858","volume":"11","author":"DP Bondeson","year":"2015","unstructured":"Bondeson DP, Mares A, Smith IE, Ko E, Campos S, Miah AH, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol. 2015;11:611\u20137.","journal-title":"Nat Chem Biol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08250-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08250-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08250-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:15:57Z","timestamp":1764180957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08250-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8250"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08250-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6284026\/v1","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"22 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Relevant clinical data and specimens utilized in this study were anonymized prior to analysis, all experimental procedures were conducted in strict accordance with relevant guidelines and regulations, including the principles outlined in the Declaration of Helsinki. All patients provided written informed consent prior to enrollment under a protocol approved by the Clinical Research Ethics Committee of Zhongshan Hospital, Fudan University (No. B2021-143R). All mouse experiments obtained approval from the Experimental Animal Ethics Committee of Zhongshan Hospital, Fudan University(No.20220120-068), and conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"855"}}